Journal
NATURE MEDICINE
Volume 18, Issue 3, Pages 375-377Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2644
Keywords
-
Funding
- National Institute of Biomedical Innovation (NiBio)
- Ministry of Health, Labour and Welfare
- National Cancer Center
- Norwegian Cancer Society
- National Cancer Center, Japan
- Grants-in-Aid for Scientific Research [23591330, 23249052, 22134006, 24390288] Funding Source: KAKEN
Ask authors/readers for more resources
We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available